The human advantage

The human advantage: The new rules of successful pharma outsourcing 

AI, automation and digitalisation are becoming increasingly embedded across pharmaceutical development and manufacturing. Significant investment is going into digital infrastructure, predictive technologies, automation and data platforms, while AI is also finding its way into commercial, quality and corporate functions. 

At Recipharm, we see the value of these technologies first-hand across development and commercial manufacturing. AI is increasingly part of how we work, helping us operate faster and more efficiently so that our teams can spend more time working directly with customers. The principle behind that is important: technology should support the work and the relationship, rather than replace it. 

As digital capabilities become more widely available across the CDMO industry, however, access to the technology itself becomes less of a differentiator. The more important question is how effectively it is used alongside scientific knowledge, operational experience and human judgement. 

Pharmaceutical development and manufacturing involve a level of complexity that cannot always be addressed through data alone. Materials vary, processes behave differently as they move between scales and equipment, and unexpected results need to be understood within the context of the product, process and manufacturing environment. This places greater emphasis on the people using the technology, and on the relationships that bring their knowledge together. 

Digital capability changes the role of human experience 

The growing use of AI does not make scientific and operational experience less important. Instead, it changes where that experience can add the greatest value. 

Digital capabilities give development and manufacturing teams access to more information and make it possible to recognise patterns across increasingly complex datasets. But pharmaceutical manufacturing takes place under conditions where variability is unavoidable. Differences between raw material lots, environmental conditions, equipment and scale can all influence how a process behaves. When performance changes unexpectedly, data can help identify what has changed. Understanding why it has changed, the potential implications for the batch or process and what needs to happen next requires a broader understanding of the product and manufacturing environment. 

Successful digital transformation also extends beyond implementing new technology. Culture, communication, alignment and organisational silos can all affect whether technology delivers its intended value. Automating an inefficient or poorly aligned process does not resolve the underlying problem. 

The real test comes when the expected path changes 

Human experience becomes particularly important when a manufacturing process does not behave as expected. 

An unexplained out-of-trend analytical peak, a change in dissolution during commercial tableting or an unexpected change in yield on an aseptic line may have several possible explanations. Digital tools can identify the anomaly quickly, but establishing its significance requires scientists and process engineers to consider the wider circumstances in which it occurred. 

Material variability, mixing shear, equipment parameters or other aspects of the process may need to be examined. Previous manufacturing experience provides a reference point beyond the individual dataset, helping teams identify which factors warrant closer investigation. 

As manufacturing data increases, it can strengthen an investigation, but scientific and operational judgement remains critical to determining what that data means. 

Tech-transfer demonstrates why knowledge cannot simply be transferred as data 

The relationship between digital information and practical experience becomes especially clear during tech-transfer. 

Digital workflows and electronic parameter mapping can standardise the transfer package and provide manufacturing teams with information established during development. But successful industrialisation requires more than transferring documented process parameters from one environment to another. 

A process moving into commercial manufacturing will encounter different equipment, scale and operating conditions. Bringing development teams together with commercial manufacturing scientists, engineers and shop-floor operators allows assumptions to be challenged before validation and helps the receiving team understand why particular process decisions were made. 

Digital systems make information easier to transfer, while interaction between teams helps ensure the knowledge behind it is understood and applied in the new manufacturing environment. 

Supply resilience is also a human challenge 

Pharmaceutical supply chains operate within an environment shaped by raw material availability, international logistics, trade restrictions and other external pressures. Digital systems can provide earlier visibility of emerging constraints and their potential impact on production. 

If a specialised single-use component, primary packaging component or excipient is delayed, maintaining supply may require alternative allocations, secondary suppliers or alternative materials and components. Quality and regulatory considerations may also need to be addressed before an alternative can be introduced. 

That response depends on procurement, planning, quality and regulatory teams working together with the customer. Supply resilience therefore combines earlier visibility with the ability to make decisions and coordinate a response when circumstances change. 

Trust becomes more important, not less 

When a pharmaceutical or biotech company chooses an outsourced commercial manufacturing partner, it is entrusting that partner with an important part of its market supply and product availability. Reliability, transparency and alignment therefore matter alongside manufacturing capability. 

This becomes particularly clear when something goes wrong. A deviation, unexpected analytical result or delay in batch release may require input across operations, quality, analytical, regulatory and customer teams. Addressing the issue depends on communicating it early, bringing the right people together and working transparently towards a resolution. 

Changing commercial manufacturing partners is itself a significant undertaking, involving qualification of a new GMP site, analytical-method transfer, process validation and regulatory variations. Maintaining an effective working relationship is therefore important to the continuity of outsourced commercial supply. 

Technical capability, capacity and modern equipment remain fundamental when selecting a CDMO, but proactive communication, reliable operational execution and transparency also matter in establishing and maintaining long-term outsourcing relationships. 

The differentiator is how people and technology work together 

The practical value of combining technology with human experience can be seen across the operational lifecycle. 

AI-enabled tools can make it quicker to assess customer requests against internal information, while automation can support batch-data collection, equipment monitoring and predictive maintenance. The information generated still needs to be interpreted by people who understand the customer, product and process. 

During tech-transfer, digital workflows provide structure and consistency, while dialogue between development and manufacturing teams helps determine whether the process will operate robustly at commercial scale. In supply planning, digital systems can identify emerging constraints while teams work with customers to manage the response. In manufacturing, automated monitoring provides process information while operators and quality teams investigate unexpected trends. 

As routine activities become increasingly automated, scientific and operational experience can be focused where judgement, interpretation and collaboration matter most. 

The future is therefore not a choice between technology and people. The greater opportunity lies in using technology to strengthen what experienced teams are able to do, providing better information, reducing unnecessary administrative work and creating more time for scientific problem-solving and customer collaboration.